Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM ACETATE versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: POTASSIUM ACETATE versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 IN PLASTIC CONTAINER.
POTASSIUM ACETATE vs POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium acetate provides potassium ions, which are essential for maintaining intracellular ionic balance, nerve conduction, muscle contraction, and acid-base equilibrium. It acts as a potassium replenisher and can also be used to alkalinize urine by converting to bicarbonate.
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.
Intravenous, 10-20 mEq/h, maximum infusion rate 20 mEq/h, not to exceed 150 mEq/day.
Intravenous infusion at a rate not exceeding 10 mEq/hour (0.75 mEq/kg/hour). Typical dose: 20-40 mEq potassium chloride in 1 liter D5W administered over 8-12 hours.
None Documented
None Documented
Not applicable as potassium is not eliminated by first-order kinetics; plasma concentration reflects body stores and renal function.
Potassium has no true elimination half-life as it is an endogenous electrolyte; redistribution half-life is approximately 1–1.5 hours for exogenous loads, reflecting cellular uptake and renal excretion. In anephric patients, half-life extends to 12–24 hours due to reliance on gastrointestinal and dialysis excretion.
Primarily renal (>90%) as potassium ions; minimal biliary/fecal.
Renal: >90% of potassium excreted by kidneys, with distal tubular secretion and reabsorption. Fecal: ~10% eliminated via gastrointestinal tract. Biliary: negligible.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement